1
|
Nitta H, Takizawa H, Mitsumori T, Iizuka-Honma H, Araki Y, Fujishiro M, Tomita S, Kishikawa S, Hashizume A, Sawada T, Okubo M, Sekiguchi Y, Ando M, Noguchi M. Possible New Histological Prognostic Index for Large B-Cell Lymphoma. J Clin Med 2023; 12:6324. [PMID: 37834968 PMCID: PMC10573887 DOI: 10.3390/jcm12196324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2023] [Revised: 09/21/2023] [Accepted: 09/26/2023] [Indexed: 10/15/2023] Open
Abstract
We conducted a retrospective analysis of GRP94 immunohistochemical (IHC) staining, an ER stress protein, on large B-cell lymphoma (LBCL) cells, intracellular p53, and 15 factors involved in the metabolism of the CHOP regimen: AKR1C3 (HO metabolism), CYP3A4 (CHOP metabolism), and HO efflux pumps (MDR1 and MRP1). The study subjects were 42 patients with LBCL at our hospital. The IHC staining used antibodies against the 17 factors. The odds ratios by logistic regression analysis used a dichotomous variable of CR and non-CR/relapse were statistically significant for MDR1, MRP1, and AKR1C3. The overall survival (OS) after R-CHOP was compared by the log-rank test. The four groups showed that Very good (5-year OS, 100%) consisted of four patients who showed negative IHC staining for both GRP94 and CYP3A4. Very poor (1-year OS, 0%) consisted of three patients who showed positive results in IHC for both GRP94 and CYP3A4. The remaining 35 patients comprised two subgroups: Good (5-year OS 60-80%): 15 patients who showed negative staining for both MDR1 and AKR1C3 and Poor (5-year OS, 10-20%): 20 patients who showed positive staining for either MDR, AKR1C3, MRP1, or p53. The Histological Prognostic Index (HPI) (the four groups: Very poor, Poor, Good, and Very good) is a breakthrough method for stratifying patients based on the factors involved in the development of treatment resistance.
Collapse
Affiliation(s)
- Hideaki Nitta
- Department of Hematology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu-shi 279-0021, Japan; (H.N.); (H.T.); (T.M.); (H.I.-H.)
| | - Haruko Takizawa
- Department of Hematology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu-shi 279-0021, Japan; (H.N.); (H.T.); (T.M.); (H.I.-H.)
| | - Toru Mitsumori
- Department of Hematology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu-shi 279-0021, Japan; (H.N.); (H.T.); (T.M.); (H.I.-H.)
| | - Hiroko Iizuka-Honma
- Department of Hematology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu-shi 279-0021, Japan; (H.N.); (H.T.); (T.M.); (H.I.-H.)
| | - Yoshihiko Araki
- Department of Pathology and Microbiology, Division of Microbiology, Nihon University School of Medicine, Itabashi-ku, Tokyo 173-8610, Japan;
| | - Maki Fujishiro
- Institute for Environmental and Gender-Specific Medicine, Juntendo University Urayasu Hospital, Chiba 279-0021, Japan;
| | - Shigeki Tomita
- Department of Diagnostic Pathology, Juntendo University Urayasu Hospital, Chiba 279-0021, Japan; (S.T.); (S.K.); (A.H.)
| | - Satsuki Kishikawa
- Department of Diagnostic Pathology, Juntendo University Urayasu Hospital, Chiba 279-0021, Japan; (S.T.); (S.K.); (A.H.)
| | - Akane Hashizume
- Department of Diagnostic Pathology, Juntendo University Urayasu Hospital, Chiba 279-0021, Japan; (S.T.); (S.K.); (A.H.)
| | - Tomohiro Sawada
- Department of Clinical Laboratory, Juntendo University Urayasu Hospital, Chiba 279-0021, Japan;
| | - Mitsuo Okubo
- Laboratory of Blood Transfusion, Juntendo University Urayasu Hospital, Chiba 279-0021, Japan;
| | | | - Miki Ando
- Division of Hematology, Juntendo University Juntendo Hospital, 3-1-3 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan;
| | - Masaaki Noguchi
- Department of Hematology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka, Urayasu-shi 279-0021, Japan; (H.N.); (H.T.); (T.M.); (H.I.-H.)
| |
Collapse
|
2
|
Takizawa H, Araki Y, Fujishiro M, Tomita S, Kishikawa S, Hashizume A, Mitsumori T, Nitta H, Iizuka-Honma H, Sawada T, Okubo M, Sekiguchi Y, Ando M, Noguchi M. Role of TGF-beta1 and TNF-alpha1 produced by neoplastic cells in the pathogenesis of fibrosis in patients with hematologic neoplasms. J Clin Exp Hematop 2023; 63:83-89. [PMID: 37121717 PMCID: PMC10410624 DOI: 10.3960/jslrt.22044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Revised: 02/17/2023] [Accepted: 02/22/2023] [Indexed: 05/02/2023] Open
Abstract
We conducted this study with the objective of elucidating the mechanism of development of fibrosis in hematologic neoplasms and develop treatments for these patients. Among the suggested mechanisms of development of fibrosis is cases of hematologic neoplasms is the production of TGF-beta1 (transforming growth factor-beta-1) and TNF-alpha1 (tumor necrotizing factor-alpha-1) by the tumor cells, both of which are fibrosis-stimulating cytokines that act on fibroblasts to promote fibrosis. However, there are few reports based on human clinical pathology studies. We conducted an immunohistochemical study on paraffin-embedded formalin-fixed specimens obtained from 104 patients with various pathologic conditions (acute leukemia, malignant lymphoma, inflammation, cancer, etc.). The association of tissue fibrosis with positive immunohistochemistry for TGF- beta1 and/or TNF-alpha1, TGF-beta1 was found to be strongly associated with tissue fibrosis, and in cases with positive immunohistochemistry for TGF-beta1, the odds ratio for fibrosis was 12.8, which was significantly high. Combined positivity for TGF-beta1 and TNF-alpha1 was also associated with a significant odds ratio for fibrosis of 3.4, suggesting that TGF-beta1 expression is an important prerequisite. TGF-beta1 has been suggested as playing a relatively important role in tissue fibrosis. Future clinical application of these cytokines for both diagnosis and treatment is expected.
Collapse
|
3
|
Yoshioka W, Sonehara K, Iida A, Oya Y, Kurashige T, Okubo M, Ogawa M, Matsuda F, Higasa K, Mori-Yoshimura M, Nakamura H, Hayashi S, Okada Y, Noguchi S, Nishino I. DISTAL MYOPATHIES. Neuromuscul Disord 2021. [DOI: 10.1016/j.nmd.2021.07.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
4
|
Okubo M, Noguchi S, Hayashi S, Komaki H, Nishino I. DMD/BMD - GENETICS. Neuromuscul Disord 2021. [DOI: 10.1016/j.nmd.2021.07.140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
5
|
Sekiguchi Y, Iizuka H, Takizawa H, Mitsumori T, Tomita S, Izumi H, Okubo M, Miyake K, Osawa T, Sawada T, Yoshikawa S, Noguchi M. Use of Ibrutinib in 10 Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in Real-World Clinical Practice -A Report from a Single Medical Institution. Gan To Kagaku Ryoho 2021; 48:921-926. [PMID: 34267029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
UNLABELLED In Japan, ibrutinib has been approved as both a front-line and later-line treatment for chronic leukemia/small lymphocytic lymphoma(CLL/SLL). However, little is known about the actual outcomes and adverse events(AEs)associated with the use of ibrutinib in Japanese patients. OBJECTIVE The outcomes and AEs of patients treated with ibrutinib in a real-world setting were investigated. METHODS A retrospective cohort study of all patients with CLL/SLL who were treated with ibrutinib at a single institution was conducted. RESULT In total, 10 patients, including 5 treatment-naïve patients(50%), were enrolled. The median follow-up period was 9.8 months(range, 0.2-21.6 months), and the estimated overall response rate (ORR: complete remission plus partial remission)was 60%. The median overall survival and progression-free survival outcomes were not reached. During the follow-up period, 4 patients(40%)had at least one AE and 1 patient(10%)had at least one grade≥3 AE. Ibrutinib was discontinued in 4 patients(40%)because of AEs in 2 patients(20%), the progression of CLL in 1 patient(10%), and financial reasons in 1 patient(10%). Richter's transformation did not occur in any of the cases. CONCLUSION The ORR was lower(60%)than that observed in clinical trials. The frequency and severity of AEs were both relatively low, although the discontinuation rate was high(40%). Patient education and medication adherence were considered important.
Collapse
|
6
|
Sekiguchi Y, Nishitani M, Takizawa H, Iizuka H, Mitsumori T, Tomita S, Izumi H, Okubo M, Miyake K, Osawa T, Sawada T, Yoshikawa S, Okura H, Noguchi M. Low‒Risk Essential Thrombocythemia Who Presented with Recurrent Episodes of Cerebral Hemorrhage during Pregnancy and Developed Cerebral Infarction during Puerperium. Gan To Kagaku Ryoho 2021; 48:725-730. [PMID: 34006724] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
A 42‒year‒old woman. At week 27 of pregnancy, she developed subcortical hemorrhage and underwent open cranial surgery for hematoma evacuation. The platelet(Plt)count was 297,000/μL. At week 34 of pregnancy, she developed subcortical hemorrhage again. The Plt count was 429,000/μL. At week 35 of pregnancy, the ventricular rupture and she underwent drainage and emergency cesarean section. The Plt count was 687,000/μL. Two days after delivery, hemorrhage was detected. The Plt count was 815,000/μL. Six days after delivery, she developed infarction. The Plt count was 915,000/μL. MRI revealed no evidence of aneurysm, arteriovenous malformations or tumor. Ten days after delivery, the Plt count was 1,173,000/μL. Bone marrow examination led to the diagnosis of essential thrombocythemia(ET). JAK2, CARL and MPL was negative. She was rated as"low‒risk"by IPSET‒thrombosis, and as"ultralow"risk by revised IPSET‒thrombosis. von Willebrand factor(VWF)activity was as high as 247%. The bleeding time and platelet aggregation activity were normal. There was no evidence of disseminated intravascular coagulation(DIC)or hypertensive disorders of pregnancy(HDP). She died of cerebral hemorrhage and infarction, 26 days after delivery.
Collapse
|
7
|
Sekiguchi Y, Wakabayashi M, Takizawa H, Iizuka H, Sakajiri S, Sugimoto K, Inano T, Fukuda Y, Hamano Y, Tomita S, Izumi H, Okubo M, Nakamura N, Sawada T, Komatsu N, Noguchi M. Relapsed refractory nodal peripheral T-cell lymphoma with follicular helper T-cell phenotype was initially resistant to pralatrexate and confirmed to be unresponsive to subsequent forodesine, but responded to re-instituted pralatrexate. J Clin Exp Hematop 2021; 60:26-28. [PMID: 32224563 PMCID: PMC7187677 DOI: 10.3960/jslrt.18031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2018] [Accepted: 01/15/2020] [Indexed: 12/05/2022] Open
|
8
|
Nakamura Y, Furuta Y, Tokida M, Ichikawa K, Shirahata M, Uzawa K, Takizawa M, Okubo M, Ohsaka A. A survey of nurses to assess transfusion practice at the bedside using an electronic identification system: Experience at a university hospital. Transfus Med 2021; 31:5-10. [PMID: 33398917 DOI: 10.1111/tme.12758] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2020] [Revised: 10/05/2020] [Accepted: 12/27/2020] [Indexed: 11/30/2022]
Abstract
OBJECTIVES The objective of this study was to assess the performance and recognition of transfusion practice at the bedside by nurses in our hospital, where a barcode-based electronic identification system (EIS) has been used since 2002. BACKGROUND More than half of the steps in the transfusion chain are dependent on nurses' awareness and skills. METHODS Our transfusion policy at the bedside includes two-person checking of the patient and two-person signing of the label at the time of collecting blood samples for pre-transfusion testing and two-person blood administration, which generally involved a doctor-nurse pair but sometimes involved two nurses. Anonymous, paper-based questionnaires were sent in January 2018 to 1051 nurses who were working in Juntendo University Hospital, Tokyo, Japan. The questionnaire consisted of three parts: (a) background of respondents, (b) performance of collection of blood samples for pre-transfusion testing and (c) performance of pre-transfusion check procedures at the bedside using an EIS based on a total of 20 questions. RESULTS There was a good response rate of individual nurses (1006/1051, 96%). Most nurses (>90%) performed two-person checking of the patient and two-person signing of the label at the time of collecting blood samples. Most nurses (>90%) performed two-person blood administration involving a doctor-nurse pair and electronic pre-transfusion check using an EIS before blood administration. CONCLUSIONS The survey revealed that most nurses complied with our transfusion policy at the bedside, but some nurses did not. Further education/training and continuous support by the transfusion service may be needed for all nurses.
Collapse
Affiliation(s)
- Yuki Nakamura
- Department of Transfusion Service, Juntendo University Hospital, Tokyo, Japan
| | - Yoshiaki Furuta
- Department of Transfusion Service, Juntendo University Hospital, Tokyo, Japan
| | - Miho Tokida
- Department of Transfusion Service, Juntendo University Hospital, Tokyo, Japan
| | - Kayoko Ichikawa
- Department of Transfusion Service, Juntendo University Hospital, Tokyo, Japan
| | - Mineko Shirahata
- Department of Nursing, Juntendo University Hospital, Tokyo, Japan
| | - Kumiko Uzawa
- Department of Nursing, Juntendo University Hospital, Tokyo, Japan
| | - Makiko Takizawa
- Department of Nursing, Juntendo University Hospital, Tokyo, Japan
| | - Mitsuo Okubo
- Department of Transfusion Service, Juntendo University Urayasu Hospital, Chiba, Japan.,Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Akimichi Ohsaka
- Department of Transfusion Service, Juntendo University Hospital, Tokyo, Japan.,Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo, Japan
| |
Collapse
|
9
|
Sekiguchi Y, Nishitani M, Takizawa H, Tomita S, Izumi H, Okubo M, Miyake K, Osawa T, Sawada T, Yoshikawa S, Noguchi M. The Current Status of Screening for Essential Thrombocythemia and Polycythemia Vera in Clinical Practice-Report from a Single Institution. Gan To Kagaku Ryoho 2021; 48:63-67. [PMID: 33468725] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
OBJECTIVE We investigate the current status of screening for essential thrombocythemia(ET)and polycythemia vera(PV), at our hospital. METHODS According to the World Health Organization(WHO)diagnostic criteria. PATIENTS All patients who visited Juntendo University Urayasu Hospital between May 1984(when the hospital opened)and January 2019. RESULT More than 90% of patients with elevated platelet counts(PLT)(n=25,062)and more than 90% of patients with elevated hemoglobin( Hb)or hematocrit(Ht)levels(n=16,422)did not visit the department of hematology, suggesting that there could be a high percentage of patients with potentially latent ET and PV visiting the hospital. In addition, a large number of patients fulfilling the laboratory criteria for ET/PV visited various departments of the hospital other than the department of hematology. CONCLUSION Because ET/PV manifests with diverse symptoms, including non-specific symptoms and symptoms pertaining to other organ systems. Based on the findings, we consider that it is essential to disseminate information about the WHO diagnostic criteria/clinical symptoms and possibility of latent ET/PV to all departments of the hospital, and to establish cooperation between the department of hematology and other departments.
Collapse
|
10
|
Okubo M, Furuta Y, Nakamura Y, Osawa T, Tada N, Sawada T, Yamatoya K, Sekiguchi Y, Araki Y, Miyake K, Noguchi M, Komatsu N, Ohsaka A. Threshold for optimal administration of plerixafor in autologous peripheral blood stem cell collections through CD34+ cell monitoring based on the experience from two Japanese university hospitals. Ther Apher Dial 2020; 25:687-696. [PMID: 33325621 DOI: 10.1111/1744-9987.13614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2020] [Revised: 11/19/2020] [Accepted: 12/13/2020] [Indexed: 12/01/2022]
Abstract
Plerixafor was introduced to Japan in 2017 as a stem cell mobilization enhancement reagent, but the threshold for its use remains unclear. In this study, we assessed 57 patients treated with plerixafor (33 patients with multiple myeloma (MM) and 24 with malignant lymphoma (ML) and 152 patients without plerixafor administration. When CD34+ cell pre-counts were between 5.5 and 20 cells/μL in MM or 6 and 21 cells/μL in ML, the CD34+ cell count increased significantly, attaining the highest yield in response to plerixafor (achievement rate by one leukapheresis is 93.3% and 91.7% in MM and ML, at P < .001 and P = .012, respectively). In case the CD34+ cell pre-count was less than 5.5 cells/μL, an increase of at least 7 cells/μL from baseline by plerixafor was the necessary condition to achieve successful collection through a two-time leukapheresis. Monitoring CD34+ cell numbers might improve the collection efficiency and reduce the cost.
Collapse
Affiliation(s)
- Mitsuo Okubo
- Department of Transfusion Service, Juntendo University Urayasu Hospital, Chiba, Japan.,Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Yoshiaki Furuta
- Department of Transfusion Service, Juntendo University Hospital, Tokyo, Japan
| | - Yuki Nakamura
- Department of Transfusion Service, Juntendo University Hospital, Tokyo, Japan
| | - Toshiya Osawa
- Department of Transfusion Service, Juntendo University Urayasu Hospital, Chiba, Japan
| | - Naoki Tada
- Department of Transfusion Service, Juntendo University Urayasu Hospital, Chiba, Japan
| | - Tomohiro Sawada
- Department of Clinical Laboratory Medicine, Juntendo University Urayasu Hospital, Chiba, Japan
| | - Kenji Yamatoya
- Institute for Environmental & Gender-specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan
| | - Yasunobu Sekiguchi
- Department of Hematology, Juntendo University Urayasu Hospital, Chiba, Japan
| | - Yoshihiko Araki
- Institute for Environmental & Gender-specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan
| | - Kazunori Miyake
- Department of Clinical Laboratory Medicine, Juntendo University Urayasu Hospital, Chiba, Japan
| | - Masaaki Noguchi
- Department of Hematology, Juntendo University Urayasu Hospital, Chiba, Japan
| | - Norio Komatsu
- Department of Hematology, Juntendo University Hospital, Tokyo, Japan
| | - Akimichi Ohsaka
- Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo, Japan
| |
Collapse
|
11
|
Kabeya Y, Okubo M, Yonezawa S, Nakano H, Inoue M, Ogasawara M, Saito Y, Tanboon J, Indrawati L, Kumutpongpanich T, Chen Y, Tokumasu R, Iwamori T, Takano A, Nishino I. OMICs AND AI APPROACHES FOR MUSCLE DISEASES. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Sekiguchi Y, Iizuka H, Takizawa H, Sugimoto K, Sakajiri S, Inano T, Fukuda Y, Shirane S, Hamano Y, Tomita S, Izumi H, Okubo M, Nakamura N, Sawada T, Sekiguchi N, Noguchi M. Methotrexate-associated Hodgkin Lymphoma in a Patient with Rheumatoid Arthritis Successfully Treated with Brentuximab Vedotin in Combination with Doxorubicin, Vinblastine, and Dacarbazine (BV+AVD). Intern Med 2020; 59:2165-2171. [PMID: 32461524 PMCID: PMC7516310 DOI: 10.2169/internalmedicine.4417-20] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/05/2022] Open
Abstract
A 53-year-old woman had been diagnosed with rheumatoid arthritis (RA) in X-6. She was started on methotrexate (MTX) in X-1. She developed a cough, and chest computed tomography showed abnormalities. In X, MTX was discontinued, but the cough persisted. A lung biopsy revealed a diagnosis of nodular sclerosis classic Hodgkin lymphoma (CHL-NS). She was considered to have "other iatrogenic immunodeficiency-associated lymphoproliferative disorders" (OIIA-LPD), MTX-associated Hodgkin lymphoma (MTX-HL). She received six courses of brentuximab vedotin (BV) in addition to AVD (BV+AVD). A complete metabolic response was obtained, and the RA went into remission. This is the fourth reported case of BV+AVD for MTX-HL.
Collapse
Affiliation(s)
| | - Hiroko Iizuka
- Department of Hematology, Juntendo University Urayasu Hospital, Japan
| | - Haruko Takizawa
- Department of Hematology, Juntendo University Urayasu Hospital, Japan
| | - Keiji Sugimoto
- Department of Hematology, Juntendo University Urayasu Hospital, Japan
| | - Sakura Sakajiri
- Department of Hematology, Juntendo University Urayasu Hospital, Japan
| | - Tadaaki Inano
- Department of Hematology, Juntendo University Hospital, Japan
| | - Yasutaka Fukuda
- Department of Hematology, Juntendo University Hospital, Japan
| | - Syuichi Shirane
- Department of Hematology, Juntendo University Hospital, Japan
| | - Yasuharu Hamano
- Department of Hematology, Juntendo University Hospital, Japan
| | - Shigeki Tomita
- Department of Pathology, Juntendo University Urayasu Hospital, Japan
| | - Hiroshi Izumi
- Department of Pathology, Juntendo University Urayasu Hospital, Japan
| | - Mitsuo Okubo
- Department of Transfusion Medicine, Juntendo University Urayasu Hospital, Japan
| | - Noriko Nakamura
- Department of Clinical Laboratory, Juntendo University Urayasu Hospital, Japan
| | - Tomohiro Sawada
- Department of Clinical Laboratory, Juntendo University Urayasu Hospital, Japan
| | | | - Masaaki Noguchi
- Department of Hematology, Juntendo University Urayasu Hospital, Japan
| |
Collapse
|
13
|
Sekiguchi Y, Wakabayashi M, Iizuka H, Takizawa H, Sugimoto K, Sakajiri S, Inano T, Fukuda Y, Hamano Y, Tomita S, Izumi H, Isogai H, Okubo M, Nakamura N, Sawada T, Matsumoto K, Noguchi M. Significant role of magnetic resonance imaging for the diagnosis and evaluation of cardiac amyloidosis in primary light chain amyloidosis. J Clin Exp Hematop 2020; 60:97-102. [PMID: 32779613 PMCID: PMC7596909 DOI: 10.3960/jslrt.19040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
A 47-year-old male with macroglossia presented with dyspnea on effort and chest pain at
rest. Cardiac MRI revealed diffuse global subendocardial late gadolinium enhancement below
the left ventricular endocardium and a dark blood pool of intracardiac contrast medium.
Tongue biopsy revealed amyloid deposition, which was limited in the myocardium. He was
diagnosed with primary light chain amyloidosis. His condition was stage I according to the
Mayo Clinic staging system. He underwent autologous peripheral blood stem cell
transplantation. On Day 10, he developed chest pain and died suddenly on Day 11.
Postmortem examination revealed amyloid deposition throughout the heart.
Collapse
Affiliation(s)
- Yasunobu Sekiguchi
- Department of Hematology, Juntendo University Urayasu Hospital, Urayasu-shi, Japan
| | - Mutsumi Wakabayashi
- Department of Hematology, Juntendo University Urayasu Hospital, Urayasu-shi, Japan
| | - Hiroko Iizuka
- Department of Hematology, Juntendo University Urayasu Hospital, Urayasu-shi, Japan
| | - Haruko Takizawa
- Department of Hematology, Juntendo University Urayasu Hospital, Urayasu-shi, Japan
| | - Keiji Sugimoto
- Department of Hematology, Juntendo University Urayasu Hospital, Urayasu-shi, Japan
| | - Sakura Sakajiri
- Department of Hematology, Juntendo University Urayasu Hospital, Urayasu-shi, Japan
| | - Tadaaki Inano
- Department of Hematology, Juntendo University Hospital, Bunkyo-ku, Japan
| | - Yasutaka Fukuda
- Department of Hematology, Juntendo University Hospital, Bunkyo-ku, Japan
| | - Yasuharu Hamano
- Department of Hematology, Juntendo University Hospital, Bunkyo-ku, Japan
| | - Shigeki Tomita
- Department of Pathology, Juntendo University Urayasu Hospital, Urayasu-shi, Japan
| | - Hiroshi Izumi
- Department of Pathology, Juntendo University Urayasu Hospital, Urayasu-shi, Japan
| | - Hiroyuki Isogai
- Department of Cardiology, Juntendo University Urayasu Hospital, Urayasu-shi, Japan
| | - Mitsuo Okubo
- Department of Transfusion Medicine, Juntendo University Urayasu Hospital, Urayasu-shi, Japan
| | - Noriko Nakamura
- Department of Laboratory Medicine, Juntendo University Urayasu Hospital, Urayasu-shi, Japan
| | - Tomohiro Sawada
- Department of Laboratory Medicine, Juntendo University Urayasu Hospital, Urayasu-shi, Japan
| | - Kimihiro Matsumoto
- Department of Internal Medicine, Tokyo Dental University Ichikawa General Hospital, Ichikawa-shi, Japan
| | - Masaaki Noguchi
- Department of Hematology, Juntendo University Urayasu Hospital, Urayasu-shi, Japan
| |
Collapse
|
14
|
Sekiguchi Y, Wakabayashi M, Takizawa H, Iizuka H, Sakajiri S, Sugimoto K, Inano T, Fukuda Y, Hamano Y, Tomita S, Izumi H, Okubo M, Nakamura N, Sawada T, Noguchi M. A Case of Primary Myelofibrosis in Which Ruxolitinib Therapy Ameliorated the Fibrosis, but Resulted in Fatty Marrow. Gan To Kagaku Ryoho 2020; 47:279-285. [PMID: 32381964] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
A 63-year-old woman was referred to our department in 2015 because of anemia and thrombocytosis. MPL W515/K was positive, JAK-2V617F and CALR exon 9 were negative. Bone marrow(BM)biopsy led to a diagnosis of primary myelofibrosis (PMF)in the prefibrotic/early stage(Grade 1). BMbiopsy performed in 2016 showed overt fibrotic stage(Grade 2). She was classified according to the Dynamic International Prognostic Scoring System(DIPSS)as intermediate(Int)-Ⅱrisk. Ruxolitinib 10 mg daily was initiated. Ruxolitinib was suspended for hepatic dysfunction after the dose was increased to 15 mg. Subsequently, ruxolitinib was resumed at 10 mg. BM biopsy performed in 2017 showed progression of myelofibrosis(MF)to Grade 3. BM biopsy performed in 2018 showed improved to Grade 0-1, however, BM was fatty. Currently in 2019, she continues to be on ruxolitinib. Results of immunohistochemical staining of BM biopsy specimens for cytokines and CD34 suggested the role of cytokines in the pathogenesis of the PMF. It was speculated that ruxolitinib blocked the production of cytokines to ameliorate the MF and restore the hematopoietic function of the BM. Although the pathogenesis of the fatty marrow remained unclear, the possibility of involvement of ruxolitinib cannot be denied.
Collapse
|
15
|
Nakamura Y, Okubo M, Furuta Y, Tokida M, Ichikawa K, Ohsaka A. Impact of CD34+ pre-counting and plerixafor on autologous peripheral blood stem cell collection in Japanese university hospitals in eight years. Transfus Apher Sci 2019; 58:102664. [PMID: 31753774 DOI: 10.1016/j.transci.2019.10.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2019] [Revised: 10/20/2019] [Accepted: 10/21/2019] [Indexed: 11/18/2022]
Abstract
OBJECTIVE Over the past decade, there have been two major advancements in autologous peripheral blood stem cell (PBSC) collection, namely enumeration of CD 34+ cells for apheresis prediction and use of plerixafor to assist mobilization of PBSC. This study aimed to investigate changes in the efficacy of PBSC collection from two Japanese university hospitals over an eight-year period. STUDY DESIGN AND METHODS A series of 399 PBSC collection procedures from 239 patients with solid malignant tumors (ST, n = 42), malignant lymphoma (ML, n = 91), multiple myeloma (MM, n = 99), and others (amyloidosis and leukemia, n = 7) from two university hospitals from 2011 to 2018 were retrospectively analyzed. We also analyzed the effects of CD34+ pre-counting and plerixafor administration in improving CD34+ cell yield. RESULTS Using CD34+ pre-count as a reference, the frequency of apheresis was reduced and the yield of CD34+ cells increased in patients with ST. When administrating plerixafor, especially with a CD34+ pre-count <20/μL, the yield of CD34+ cells was significantly increased in patients with ML (p = 0.02) and MM (p = 0.03). CONCLUSIONS We verified that CD34+ cell counting and plerixafor administration contributed to effective PBSC collections in our hospitals for the eight-year study period. In patients with ST, CD34+ pre-count threshold for starting apheresis was ≥10/μL. CD34+ pre-count (<20/μL) was useful to select appropriate patients for plerixafor administration among the patients with ML and MM.
Collapse
Affiliation(s)
- Yuki Nakamura
- Department of Transfusion Service, Juntendo University Hospital, Tokyo, Japan.
| | - Mitsuo Okubo
- Department of Transfusion Service, Juntendo University Urayasu Hospital, Chiba, Japan; Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo, Japan.
| | - Yoshiaki Furuta
- Department of Transfusion Service, Juntendo University Hospital, Tokyo, Japan.
| | - Miho Tokida
- Department of Transfusion Service, Juntendo University Hospital, Tokyo, Japan.
| | - Kayoko Ichikawa
- Department of Transfusion Service, Juntendo University Hospital, Tokyo, Japan.
| | - Akimichi Ohsaka
- Department of Transfusion Service, Juntendo University Hospital, Tokyo, Japan; Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo, Japan.
| |
Collapse
|
16
|
Shimizu-Motohashi Y, Takeshita E, Ishiyama A, Mori-Yoshimura M, Oya Y, Nonaka I, Maruo K, Okubo M, Saito Y, Nishino I, Sasaki M, Komaki H. P.344Assessment of longitudinal developmental milestones in Fukuyama congenital muscular dystrophy. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
17
|
Emori H, Kubo T, Tanigaki T, Kawase Y, Shiono Y, Shimamura K, Sobue Y, Matsuo Y, Hirata T, Kitabata H, Ota H, Ino Y, Okubo M, Matsuo H, Akasaka T. P1252Diagnostic performance of quantitative flow ratio from coronary angiography versus fractional flow reserve from computed tomography. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
QFR and FFRCT are recently developed, less-invasive techniques for functional assessment of coronary artery disease.
Objectives
We compared the diagnostic performance between fractional flow reserve derived from computed tomography (FFRCT) and quantitative flow ratio (QFR) derived from coronary angiography, using FFR as the standard reference.
Methods
We measured FFRCT, QFR and FFR in 152 patients (233 vessels) with stable coronary artery disease.
Results
QFR was highly correlated with FFR (r=0.78, p<0.001), while FFRCT was moderately correlated with FFR (r=0.63, p<0.001). Both QFR and FFRCT showed good agreements with FFR, presenting small values of mean difference and root-mean-squared deviation (FFR -QFR: 0.02±0.09 and FFR -FFRCT: 0.03±0.11). The AUC of QFR was significantly greater than that of 3D-QCA-derived %DS (0.93 vs. 0.78; difference: 0.15; 95% CI: 0.09 to 0.20; p<0.001). The AUC of FFRCTwas significantly greater than that of CCTA-derived %DS (0.82 vs. 0.70; difference: 0.12; 95% CI: 0.05 to 0.19; p<0.001). The AUC of QFR was significantly greater than that of FFRCT (0.93 vs. 0.82; difference: 0.11; 95% CI: 0.05 to 0.16; p<0.001). The sensitivity, specificity, positive predictive value, and negative predictive valueof QFR ≤0.80 for predicting FFR ≤0.80 were 90%, 82%, 81%, and 90%, respectively. Those of FFRCT ≤0.80 for predicting FFR ≤0.80 were 82%, 70%, 70%, and 82%, respectively. The diagnostic accuracy of QFR ≤0.80 for predicting FFR ≤0.80 was 85% [95% confidence interval: 81% to 89%], while that of FFRCT≤0.80 for predicting FFR ≤0.80was 76% [95% confidence interval: 70% to 80%].
Figure 1. Comparison of FFR ≤0.80 predictors
Conclusions
Both QFR and FFRCTpossessed the ability to accurately evaluate the functional severity of coronary stenosis.
Collapse
Affiliation(s)
- H Emori
- Wakayama Medical University, Division of cardiovascular medicine, Wakayama, Japan
| | - T Kubo
- Wakayama Medical University, Division of cardiovascular medicine, Wakayama, Japan
| | | | | | - Y Shiono
- Wakayama Medical University, Division of cardiovascular medicine, Wakayama, Japan
| | - K Shimamura
- Wakayama Medical University, Division of cardiovascular medicine, Wakayama, Japan
| | - Y Sobue
- Gifu Heart Center, Gifu, Japan
| | - Y Matsuo
- Wakayama Medical University, Division of cardiovascular medicine, Wakayama, Japan
| | | | - H Kitabata
- Wakayama Medical University, Division of cardiovascular medicine, Wakayama, Japan
| | - H Ota
- Gifu Heart Center, Gifu, Japan
| | - Y Ino
- Wakayama Medical University, Division of cardiovascular medicine, Wakayama, Japan
| | - M Okubo
- Gifu Heart Center, Gifu, Japan
| | | | - T Akasaka
- Wakayama Medical University, Division of cardiovascular medicine, Wakayama, Japan
| |
Collapse
|
18
|
Ota H, Omori H, Tanigaki T, Okamoto S, Hirata T, Kikuchi J, Sobue Y, Miyake T, Kawamura I, Kawase Y, Okubo M, Kamiya H, Tsuchiya K, Matsuo H. 6108Efficacy of the PCSK9 inhibitor for lipid-rich coronary plaque reduction: a near-infrared spectroscopy analysis. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Recently, some studies have highlighted proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors produce incremental low-density lipoprotein cholesterol (LDL-C) lowering effect. However, it is unknown whether the lipid composition of plaque changes is associated with serum LDL-C reduction due to PCSK9 inhibitors administration.
Purpose
The purpose of this study was to determine the effects of PCSK9 inhibitor (PCSK9i) on coronary plaque component in patients with a history of coronary artery disease (CAD) assessed by near-infrared spectroscopy intravascular ultrasound (NIRS-IVUS).
Methods
A total of 67 non-culprit coronary segments were identified in 34 patients. These lesions were analyzed utilizing NIRS-IVUS at baseline and follow-up coronary angiography (CAG). The subjects were divided into two groups according to lipid-lowering treatment; administration of PCSK9i group (PCSK9i: 19 segments, 9 patients) and traditional statin treatment group (Control: 48 segments, 25 patients). The change of lipid-rich plaque distribution between baseline and follow-up NIRS-IVUS was defined as the change of maximal lipid core burden index (LCBI) score for each of the 4-mm longitudinal segments (maxLCBI4mm).
Results
Mean duration from baseline to follow-up CAG was 239.4±52.4 days in the PCSK9i group and 341.0±84.1 days in the Control group (p<0.001). Despite the higher total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) in the PCSK9i group at baseline (206.6±40.9 mg/dl vs. 168.5±37.1 mg/dl, 131.5±35.4 mg/dl vs. 100.0±29.5 mg/dl; respectively, p<0.001 for both), the PCSK9i group was significantly lower TC and LDL-C at the follow-up (111.5±23.5 mg/dl vs. 157.4±27.8 mg/dl, 40.8±15.7 mg/dl vs. 86.2±19.6 mg/dl; respectively, p<0.001 for both). Furthermore, the PCSK9i group induced greater regression of maxLCBI4mm than that of Control group (99.6±156.6 vs. 27.9±118.0, p=0.046) (Figure).
Figure 1
Conclusion
Compared with traditional statin therapy, PCSK9i treatment resulted in a greater decrease in lipid component in non-culprit coronary plaques. Therefore, PCSK9i may be useful option in preventing from adverse coronary events for the patients with CAD.
Collapse
Affiliation(s)
- H Ota
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - H Omori
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - T Tanigaki
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - S Okamoto
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - T Hirata
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - J Kikuchi
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - Y Sobue
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - T Miyake
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - I Kawamura
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - Y Kawase
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - M Okubo
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - H Kamiya
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - K Tsuchiya
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - H Matsuo
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| |
Collapse
|
19
|
Habara M, Tsuchikane E, Nasu K, Kinoshita Y, Terashima M, Matsubara T, Murata A, Suzuki Y, Kawase Y, Okubo M, Matsuo H, Suzuki T. P974Efficacy of plaque debulking for bifurcated or ostial lesion by directional coronary atherectomy before 2nd generation drug eluting stent (PERFECT2). Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Objectives
We sought to evaluate the efficacy of plaque debulking by directional coronary atherectomy (DCA) before 2nd generation drug-eluting stent (DES) implantation for bifurcated coronary lesions.
Background
Percutaneous coronary intervention (PCI) for bifurcated lesions still remains complex and challenging in terms of restenosis or stent thrombosis regardless of whether simple or complex stenting used.
Methods
Patients with bifurcated lesions were enrolled in this prospective multicenter registry. Pre-2nd generation DES plaque debulking with a novel DCA was conducted. All patients were scheduled to perform a follow up (9–12 months) angiography (coronary angiography or coronary computed tomography). The primary end point was the target vessel failure (TVF) at follow-up. Secondary end points were procedure-related events and major adverse cardiac events at 1 year.
Results
A total of 77 patients with bifurcated lesions were enrolled. PCI with DCA was performed successfully in all without any major procedure-related event and only 1 case needed complex stenting. TVF rate at 9–12 months follow up was 3.9% (3 of 77) and those were all associated with revascularization of the target vessel. Restenosis was only observed at ostial of main-branch in 3cases. No death, no coronary artery bypass grafting, and no myocardial infarction were reported in the patients within the first year.
Figure1
Conclusion
DCA before 2nd generation DES implantation can possibly avoid complex stenting and provide a good mid-term outcome in patients with bifurcated lesions.
Acknowledgement/Funding
None
Collapse
Affiliation(s)
- M Habara
- Toyohashi Heart Center, Toyohashi, Japan
| | | | - K Nasu
- Toyohashi Heart Center, Toyohashi, Japan
| | | | | | | | - A Murata
- Nagoya Heart Center, Cardiovascular medicine, Nagoya, Japan
| | - Y Suzuki
- Nagoya Heart Center, Cardiovascular medicine, Nagoya, Japan
| | | | - M Okubo
- Gifu Heart Center, Gifu, Japan
| | | | - T Suzuki
- Toyohashi Heart Center, Toyohashi, Japan
| |
Collapse
|
20
|
Hayashi S, Noguchi S, Kumutpongpanich T, Iida A, Okubo M, Matsuo M, Nishino I. P.106Mutation-specific therapy for X-linked myotubular myopathy. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
21
|
Okubo M, Iida A, Inoue M, Saito Y, Ogasawara M, Hayashi S, Noguchi S, Nishino I. EP.102Genetic diagnosis in large Japanese cohort using targeted re-sequencing system. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.508] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
22
|
Indrawati L, Noguchi S, Tanboon J, Ogasawara M, Saito Y, Kumutpongpanich T, Inoue M, Okubo M, Fukuda T, Sugie H, Goto Y, Iida A, Hayashi S, Nishino I. P.89Infantile-onset lipid storage myopathy. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
23
|
Ishiguro K, Nakayama T, Yoshioka M, Murakami T, Kajino S, Shichiji M, Sato T, Fukuyo N, Kuru S, Osawa M, Nagata S, Okubo M, Murakami N, Hayashi Y, Nishino I, Ishigaki K. EP.31Characteristic findings of skeletal muscle MRI in caveolinopathies. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
24
|
Kabeya Y, Iwamori T, Yonezawa S, Takeuchi Y, Nakano H, Nagisa Y, Okubo M, Inoue M, Tokumasu R, Ozawa I, Takano A, Nishino I. O.37AI-based muscle histopathologist can differentiate major muscular dystrophies better than human. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
25
|
Sekiguchi Y, Wakabayashi M, Takizawa H, Iizuka H, Sakajiri S, Sugimoto K, Inano T, Fukuda Y, Hamano Y, Hirano T, Sato E, Aritaka N, Yahata Y, Morita K, Okamura T, Tomita S, Izumi H, Okubo M, Nakamura N, Sawada T, Noguchi M. Retrospective Analysis of 20 Patients with DLBCL Who Received MCVAC Followed by Autologous Peripheral Blood Stem Cell Transplantation. Gan To Kagaku Ryoho 2019; 46:1265-1273. [PMID: 31501368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
Autologous peripheral blood stem cell transplantation(auto-PBSCT)combined with high-dose chemotherapy has been considered as the standard therapy for relapsed or induction therapy-refractory aggressive lymphomas sensitive to chemotherapy. While various regimens have been applied as the conditioning,none has yet been established as the standard. We have begun to employ high-dose ranimustine,cytarabine,etoposide and cyclophosphamide(MCVAC)regimen. The present study was undertaken to review the efficacy and safety of MCVAC. Regimen: We carried out a retrospective analysis of 20 patients diagnosed as diffuse large B-cell lymphoma. The median follow-up duration of 20 patients was 13.05 months(range, 0.57-49.5 months). The 4-year OS and PFS were 57.8% and 30.2%,respectively. Relapse was the most frequent cause of treatment failure(n=7). The major toxicities were anorexia/nausea(95%),diarrhea (75%),hypokalemia (70%). One patient died of hepatic veno-occlusive disease(VOD). The serious adverse events included hypokalemia,arrhythmia,cerebral hemorrhage,and heart failure(1 case[5%]each). There was 1 case of a late-onset adverse event: therapy-related myelo- dysplastic syndrome/acute myeloblastic leukemia(MDS/AML). MCVAC regimen was concluded as effective and well-toler- ated. However,we should carefully monitored for the possible development of VOD and MDS/AML. Further follow-up is needed to evaluate the long-term efficacy and safety.
Collapse
|
26
|
Sekiguchi Y, Wakabayashi M, Takizawa H, Iizuka H, Sakajiri S, Sugimoto K, Inano T, Fukuda Y, Hamano Y, Tomita S, Izumi H, Okubo M, Nakamura N, Sawada T, Noguchi M. A Case of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Aspergillus Brain Abscess and Invasive Pulmonary Aspergillosis Successfully Treated with Voriconazole Followed by Cord Blood Transplantation. Gan To Kagaku Ryoho 2019; 46:1203-1209. [PMID: 31296832] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
A 59-year-old female was diagnosed as pulmonary aspergillosis(IPA)while remission induction therapy for Philadelphia chromosome-positive acute lymphoblastic leukemia. Liposomal amphotericin B improved the fungal serodiagnostic markers, however,the IPA worsened. She also developed an Aspergillus brain abscess,which, while being undetectable on CT,was detected as multiple nodular lesions by MRI. A definitive diagnosis was made by polymerase chain reaction(PCR)of brain biopsy specimens. Voriconazole(VRCZ)was effective,and cord blood transplantation was performed. She has received VRCZ for a long time. There are no relapse of either the IPA or the Aspergillus brain abscess.
Collapse
|
27
|
Sekiguchi Y, Wakabayashi M, Takizawa H, Iizuka H, Sakajiri S, Sugimoto K, Inano T, Fukuda Y, Hamano Y, Tomita S, Izumi H, Okubo M, Nakamura N, Sawada T, Noguchi M. Clinical Evaluation of the Efficacy and Safety of Anagrelide Used with or without Hydroxycarbamide in Japanese Patients with Essential Thrombocythemia-A Retrospective Single-Center Study of 35 Cases. Gan To Kagaku Ryoho 2019; 46:1141-1150. [PMID: 31296820] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
OBJECTIVE The clinical features(CF), laboratory data, disease transformation pattern and drug metabolism in essential thrombocythemia(ET)differ between Japan and Western countries. The CF of ET in clinical practice(CP)are more diverse than in prospective clinical studies. We should conduct retrospective analyses in CP. The present study was aimed at evaluating the efficacy, safety and tolerability of anagrelide(ANA)monotherapy and combined ANA plus hydroxycarbamide(HC)in Japanese ET. PATIENTS AND METHODS We have a total of 35 cases. Sixteen patients received ANA monotherapy, 10 received ANA plus HC, and 9 received ANA plus other drugs. RESULTS Comparison among three groups revealed the absence of differences in response rate(platelet count C60×10 / / 4/mL, platelet count C40×104/mL)(43.8%, 6.3% vs. 50.0%, 10.0% vs. 44.4%, 11.1%), treatment continuation rate(81.3% vs. 40.0% vs. 55.6%), median daily dose of ANA(1.00 mg in all three groups)or median treatment period(days)(259 vs. 198.5 vs. 161.0), the treatment continuation rate tended to be lower in the combined ANA plus HC. The incidence of all adverse events(AEs)was higher in the ANA monotherapy(45.7%)than ANA plus HC(28.6%)or ANA plus other drugs(25.7%), the AEs were mild in all groups. CONCLUSION The tolerability of ANA monotherapy, ANA plus HC, and ANA plus other drugs were good.
Collapse
|
28
|
Inoue M, Tanboon J, Okubo M, Theerawat K, Saito Y, Ogasawara M, Indrawati LA, Uruha A, Okiyama N, Fujimoto M, Suzuki S, Nishino I. Absence of sarcoplasmic myxovirus resistance protein A (MxA) expression in antisynthetase syndrome in a cohort of 194 cases. Neuropathol Appl Neurobiol 2019; 45:523-524. [DOI: 10.1111/nan.12551] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- M. Inoue
- Department of Neuromuscular Research National Institute of Neuroscience National Center of Neurology and Psychiatry Tokyo Japan
- Medical Genome Center National Center of Neurology and Psychiatry Tokyo Japan
| | - J. Tanboon
- Department of Neuromuscular Research National Institute of Neuroscience National Center of Neurology and Psychiatry Tokyo Japan
- Medical Genome Center National Center of Neurology and Psychiatry Tokyo Japan
| | - M. Okubo
- Department of Neuromuscular Research National Institute of Neuroscience National Center of Neurology and Psychiatry Tokyo Japan
- Medical Genome Center National Center of Neurology and Psychiatry Tokyo Japan
| | - K. Theerawat
- Department of Neuromuscular Research National Institute of Neuroscience National Center of Neurology and Psychiatry Tokyo Japan
- Medical Genome Center National Center of Neurology and Psychiatry Tokyo Japan
| | - Y. Saito
- Department of Neuromuscular Research National Institute of Neuroscience National Center of Neurology and Psychiatry Tokyo Japan
- Medical Genome Center National Center of Neurology and Psychiatry Tokyo Japan
| | - M. Ogasawara
- Department of Neuromuscular Research National Institute of Neuroscience National Center of Neurology and Psychiatry Tokyo Japan
- Medical Genome Center National Center of Neurology and Psychiatry Tokyo Japan
| | - L. A. Indrawati
- Department of Neuromuscular Research National Institute of Neuroscience National Center of Neurology and Psychiatry Tokyo Japan
- Medical Genome Center National Center of Neurology and Psychiatry Tokyo Japan
| | - A. Uruha
- Department of Neurology Tokyo Metropolitan Neurological Hospital Tokyo Japan
| | - N. Okiyama
- Department of Dermatology Faculty of Medicine University of Tsukuba Ibaraki Japan
| | - M. Fujimoto
- Department of Dermatology Graduate School of Medicine Osaka University Osaka Japan
| | - S. Suzuki
- Department of Neurology Keio University School of Medicine Tokyo Japan
| | - I. Nishino
- Department of Neuromuscular Research National Institute of Neuroscience National Center of Neurology and Psychiatry Tokyo Japan
- Medical Genome Center National Center of Neurology and Psychiatry Tokyo Japan
| |
Collapse
|
29
|
Okubo M, Nishida E, Watanabe A, Nishizaki N, Obinata K, Azuma F, Matsuhashi M, Watanabe-Okochi N, Tsuno NH, Miyake K, Yamaguchi M, Yoshida K, Ohsaka A. Marked thrombocytopenia in a neonate is associated with anti-HPA-5b, anti-HLA-A31, and anti-HLA-B55 antibodies. Pediatr Blood Cancer 2019; 66:e27555. [PMID: 30488611 DOI: 10.1002/pbc.27555] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/09/2018] [Revised: 10/03/2018] [Accepted: 10/25/2018] [Indexed: 11/09/2022]
Abstract
Maternal antibodies against human platelet antigen (HPA) and/or human leukocyte antigen (HLA) cause fetal and neonatal alloimmune thrombocytopenia (FNAIT) in 0.09-0.15% of live births. Severe cases account for 5-31% and the frequency of multiple kinds of alloantibodies is 6.9-9% of FNAIT. We present a case of severe FNAIT associated with anti-HPA-5b, anti-HLA-A31, and anti-HLA-B55 antibodies, successfully treated with immunoglobulin and platelet transfusion. The anti-HLA-B55 antibody was detected in the newborn's serum, but disappeared on the 20th day, which was followed by an increase of the platelet count. These findings suggested the potential involvement of an anti-HLA antibody in the pathogenesis of FNAIT.
Collapse
Affiliation(s)
- Mitsuo Okubo
- Department of Transfusion Service, Juntendo University Urayasu Hospital, Urayasu City, Japan.,Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - Eriko Nishida
- Department of Pediatrics, Juntendo University Urayasu Hospital, Urayasu City, Japan
| | - Akiko Watanabe
- Department of Pediatrics, Juntendo University Urayasu Hospital, Urayasu City, Japan
| | - Naoto Nishizaki
- Department of Pediatrics, Juntendo University Urayasu Hospital, Urayasu City, Japan
| | - Kaoru Obinata
- Department of Pediatrics, Juntendo University Urayasu Hospital, Urayasu City, Japan
| | - Fumihiro Azuma
- Laboratory Department, Kanto-Koshinetsu Block Blood Center, Japanese Red Cross, Tokyo, Japan
| | - Mika Matsuhashi
- Laboratory Department, Kanto-Koshinetsu Block Blood Center, Japanese Red Cross, Tokyo, Japan
| | - Naoko Watanabe-Okochi
- Laboratory Department, Kanto-Koshinetsu Block Blood Center, Japanese Red Cross, Tokyo, Japan
| | - Nelson Hirokazu Tsuno
- Laboratory Department, Kanto-Koshinetsu Block Blood Center, Japanese Red Cross, Tokyo, Japan
| | - Kazunori Miyake
- Department of Laboratory Medicine, Juntendo University Urayasu Hospital, Urayasu City, Japan
| | | | - Koyo Yoshida
- Department of Obstetrics and Gynecology, Juntendo University Urayasu Hospital, Urayasu City, Japan
| | - Akimichi Ohsaka
- Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo, Japan
| |
Collapse
|
30
|
Hirata T, Tanigaki T, Kawase Y, Hirakawa A, Omori H, Okamoto S, Ota H, Sobue Y, Kikuchi J, Okubo M, Kamiya H, Kawasaki M, Suzuki T, Pijls NHJ, Matsuo H. Post-occlusional hyperemia for fractional flow reserve assessment and pull-back curve analysis. Cardiovasc Interv Ther 2019; 35:142-149. [PMID: 30788697 DOI: 10.1007/s12928-019-00579-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2018] [Accepted: 02/12/2019] [Indexed: 11/25/2022]
Abstract
Balloon occlusion is a potential method for inducing hyperemia to measure post-percutaneous coronary intervention (PCI) fractional flow reserve (FFR). The objective of this study was to determine the clinical usefulness of post-occlusional hyperemia. FFRs measured using post-occlusional hyperemia caused by 30 (FFRoccl30) and 60 s (FFRoccl60) of balloon occlusion after PCI were compared in 60 lesions from 60 patients. The duration of hyperemia was also measured. There was a strong correlation between FFRoccl30 and FFRoccl60 (r = 0.969, p < 0.01). The duration of hyperemia was significantly longer with FFRoccl60 than with FFRoccl30 (68 ± 23 vs. 37 ± 15 s, p < 0.01). The time required for pullback curve analysis was around 45 s. However, in 7 (12%) cases, the duration of hyperemia with FFRoccl60 was < 45 s, which was not enough for pull-back curve analysis. To predict the duration of hyperemia with FFRoccl60 ≥ 45 s, the receiver operating characteristic curve analysis revealed a cut-off value of 25 s of hyperemia with FFRoccl30. FFRoccl30 is sufficient for diagnostic purposes. FFRoccl60 is suitable for pull-back curve analysis in select cases based on predictions made using the duration of hyperemia with FFRoccl30.
Collapse
Affiliation(s)
- T Hirata
- Department of Cardiovascular Medicine, Gifu Heart Center, 4-14-4 Yabutaminami, Gifu city, 5008384, Gifu, Japan
| | - T Tanigaki
- Department of Cardiovascular Medicine, Gifu Heart Center, 4-14-4 Yabutaminami, Gifu city, 5008384, Gifu, Japan
| | - Y Kawase
- Department of Cardiovascular Medicine, Gifu Heart Center, 4-14-4 Yabutaminami, Gifu city, 5008384, Gifu, Japan.
| | - A Hirakawa
- Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
| | - H Omori
- Department of Cardiovascular Medicine, Gifu Heart Center, 4-14-4 Yabutaminami, Gifu city, 5008384, Gifu, Japan
| | - S Okamoto
- Department of Cardiovascular Medicine, Gifu Heart Center, 4-14-4 Yabutaminami, Gifu city, 5008384, Gifu, Japan
| | - H Ota
- Department of Cardiovascular Medicine, Gifu Heart Center, 4-14-4 Yabutaminami, Gifu city, 5008384, Gifu, Japan
| | - Y Sobue
- Department of Cardiovascular Medicine, Gifu Heart Center, 4-14-4 Yabutaminami, Gifu city, 5008384, Gifu, Japan
| | - J Kikuchi
- Department of Cardiovascular Medicine, Gifu Heart Center, 4-14-4 Yabutaminami, Gifu city, 5008384, Gifu, Japan
| | - M Okubo
- Department of Cardiovascular Medicine, Gifu Heart Center, 4-14-4 Yabutaminami, Gifu city, 5008384, Gifu, Japan
| | - H Kamiya
- Department of Cardiovascular Medicine, Gifu Heart Center, 4-14-4 Yabutaminami, Gifu city, 5008384, Gifu, Japan
| | - M Kawasaki
- Department of Cardiology, Gifu University Graduate School of Medicine, Gifu, Japan
| | - T Suzuki
- Department of Cardiovascular Medicine, Gifu Heart Center, 4-14-4 Yabutaminami, Gifu city, 5008384, Gifu, Japan
| | - N H J Pijls
- Department of Cardiology, Catharina Hospital, Eindhoven, Netherlands
| | - H Matsuo
- Department of Cardiovascular Medicine, Gifu Heart Center, 4-14-4 Yabutaminami, Gifu city, 5008384, Gifu, Japan
| |
Collapse
|
31
|
Omori H, Witberg G, Kawase Y, Tanigaki T, Okamoto S, Hirata T, Sobue Y, Ota H, Kamiya H, Okubo M, Valzer O, Kornowski R, Matsuo H. Angiogram based fractional flow reserve in patients with dual/triple vessel coronary artery disease. Int J Cardiol 2019; 283:17-22. [PMID: 30819589 DOI: 10.1016/j.ijcard.2019.01.072] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/17/2018] [Revised: 12/06/2018] [Accepted: 01/21/2019] [Indexed: 01/29/2023]
Abstract
OBJECTIVE To assess the performance of angiography derived Fractional Flow Reserve (FFRangio) in multivessel disease (MVD) patients undergoing angiography. BACKGROUND FFR is the reference standard for physiologic assessment of coronary stenosis and guidance of revascularization, especially in patients with MVD, yet it remains grossly underutilized. The non-wire based FFRangio performs well in non-MVD patients, but its accuracy in MVD is unknown. METHODS A prospective clinical study was conducted at Gifu Heart Centre, Japan. Patients underwent physiologic assessment of all relevant coronary lesions using wire-based FFR (wbFFR) and FFRangio. Primary outcome was diagnostic performance (sensitivity, specificity, accuracy) for FFRangio with wbFFR as reference. Other outcomes were the correlation between wbFFR/FFRangio, time required for wbFFR/FFRangio measurements, and the effect of wbFFR/FFRangio on the reclassification of coronary disease severity. RESULTS Fifty patients (118 lesions in total) were included. Mean age was 72 ± 9 years, 72% were male, 36% had triple vessel disease and the average SYNTAX score was 13. The mean measurement of wbFFR and FFRangio were 0.83 ± 0.12 and 0.81 ± 0.11, respectively. Accuracy, sensitivity and specificity for FFRangio were 92.3% (95% CI 79.1-98.4%), 92.4% (95% CI 84.3-97.2%) and 92.4% (95% CI 87.4-97.3%), respectively. Pearson's r between wbFFR and FFRangio was 0.83. FFRangio measurement was faster than wbFFR (9.6 ± 3.4 vs. 15.0 ± 8.9 min, p < 0.001). CONCLUSIONS In patients with MVD, FFRangio shows good correlation and excellent diagnostic performance compared to wbFFR, and measuring FFRangio is faster than wbFFR. These results highlight the potential clinical benefits of utilizing FFRangio among patients with MVD.
Collapse
Affiliation(s)
- H Omori
- Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan
| | - G Witberg
- Department of Cardiology, Rabin Medical Center, Petah-Tikva, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
| | - Y Kawase
- Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan
| | - T Tanigaki
- Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan
| | - S Okamoto
- Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan
| | - T Hirata
- Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan
| | - Y Sobue
- Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan
| | - H Ota
- Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan
| | - H Kamiya
- Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan
| | - M Okubo
- Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan
| | - O Valzer
- Department of Cardiology, Rabin Medical Center, Petah-Tikva, Israel; CathWorks, Kfar-Saba, Israel
| | - R Kornowski
- Department of Cardiology, Rabin Medical Center, Petah-Tikva, Israel; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - H Matsuo
- Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan
| |
Collapse
|
32
|
Kumutpongpanich T, Hayashi S, Iida A, Okubo M, Matsuo M, Noguchi S, Nishino I. CONGENITAL MYOPATHIES (CNM). Neuromuscul Disord 2018. [DOI: 10.1016/j.nmd.2018.06.165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
33
|
Kabeya Y, Takeuchi Y, Nakano H, Okubo M, Inoue M, Tokumasu R, Ozawa I, Takano A, Iwamori T, Yonezawa S, Nishino I. NEXT GENERATION SEQUENCING AND EXPERIMENTAL MYOLOGY. Neuromuscul Disord 2018. [DOI: 10.1016/j.nmd.2018.06.432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
34
|
Ota H, Tanigaki T, Okamoto S, Omori H, Hirata T, Kikuchi J, Kawase Y, Okubo M, Kamiya H, Matsuo H. P2635Association between near-infrared spectroscopy and coronary computed tomographic angiography for lipid containing coronary plaques. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p2635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- H Ota
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - T Tanigaki
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - S Okamoto
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - H Omori
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - T Hirata
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - J Kikuchi
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - Y Kawase
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - M Okubo
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - H Kamiya
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - H Matsuo
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| |
Collapse
|
35
|
Ota H, Tanigaki T, Okamoto S, Omori H, Hirata T, Kikuchi J, Kawase Y, Okubo M, Kamiya H, Matsuo H. P750Impact of lipid plaque component reduction during percutaneous coronary intervention on cardiac troponin elevation after procedure: a near-infrared spectroscopy analysis. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.p750] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- H Ota
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - T Tanigaki
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - S Okamoto
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - H Omori
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - T Hirata
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - J Kikuchi
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - Y Kawase
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - M Okubo
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - H Kamiya
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| | - H Matsuo
- Gifu Heart Center, Department of Cardiology, Gifu, Japan
| |
Collapse
|
36
|
Sobue Y, Matsuo H, Kawase Y, Kondo T, Tanigaki T, Okamoto S, Omori H, Hirata T, Kikuchi J, Ota H, Kawamura I, Okubo M, Kamiya H, Suzuki T. P1784Risk stratification with combined FFR-CT and Agatston score in patient with suspected coronary artery disease. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Y Sobue
- Gifu Heart Center, Gifu, Japan
| | | | | | - T Kondo
- Gifu Heart Center, Gifu, Japan
| | | | | | - H Omori
- Gifu Heart Center, Gifu, Japan
| | | | | | - H Ota
- Gifu Heart Center, Gifu, Japan
| | | | - M Okubo
- Gifu Heart Center, Gifu, Japan
| | | | - T Suzuki
- Toyohashi Heart Center, Toyohashi, Japan
| |
Collapse
|
37
|
Marumo F, Kamata K, Okubo M. Deranged Concentrations of Water-Soluble Vitamins in the Blood of Undialyzed and Dialyzed Patients with Chronic Renal Failure. Int J Artif Organs 2018. [DOI: 10.1177/039139888600900107] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- F. Marumo
- Department of Medicine Kitasato University School of Medicine Sagamihara, Kanagawa 228, Japan
| | - K. Kamata
- Department of Medicine Kitasato University School of Medicine Sagamihara, Kanagawa 228, Japan
| | - M. Okubo
- Department of Medicine Kitasato University School of Medicine Sagamihara, Kanagawa 228, Japan
| |
Collapse
|
38
|
Ogawa T, Kimoto S, Nakashima Y, Furuse N, Ono M, Furokawa S, Okubo M, Yamaguchi H, Kawai Y. Differences in pain thresholds elicited by intraoral electrical stimuli between individuals with and without diabetes mellitus. J Oral Rehabil 2018; 45:235-239. [DOI: 10.1111/joor.12601] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/20/2017] [Indexed: 11/30/2022]
Affiliation(s)
- T. Ogawa
- Removable Prosthodontics; Nihon University Graduate School of Dentistry at Matsudo; Matsudo Japan
| | - S. Kimoto
- Department of Removable Prosthodontics; Nihon University School of Dentistry at Matsudo; Matsudo Japan
| | - Y. Nakashima
- Department of Removable Prosthodontics; Nihon University School of Dentistry at Matsudo; Matsudo Japan
| | - N. Furuse
- Removable Prosthodontics; Nihon University Graduate School of Dentistry at Matsudo; Matsudo Japan
| | - M. Ono
- Removable Prosthodontics; Nihon University Graduate School of Dentistry at Matsudo; Matsudo Japan
| | - S. Furokawa
- Removable Prosthodontics; Nihon University Graduate School of Dentistry at Matsudo; Matsudo Japan
| | - M. Okubo
- Department of Removable Prosthodontics; Nihon University School of Dentistry at Matsudo; Matsudo Japan
| | - H. Yamaguchi
- Department of Anesthesiology; Nihon University School of Dentistry at Matsudo; Matsudo Japan
| | - Y. Kawai
- Department of Removable Prosthodontics; Nihon University School of Dentistry at Matsudo; Matsudo Japan
| |
Collapse
|
39
|
Koike Y, Okubo M, Kiyohara T, Fukuchi R, Sato Y, Kuwatsuka S, Takeichi T, Akiyama M, Sugiura K, Utani A. Granulocyte and monocyte apheresis can control juvenile generalized pustular psoriasis with mutation ofIL36RN. Br J Dermatol 2017; 177:1732-1736. [DOI: 10.1111/bjd.15509] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/22/2017] [Indexed: 12/25/2022]
Affiliation(s)
- Y. Koike
- Department of Dermatology; Nagasaki University Graduate School of Biomedical Sciences; Nagasaki Japan
| | - M. Okubo
- Department of Dermatology; Nagasaki University Graduate School of Biomedical Sciences; Nagasaki Japan
| | - T. Kiyohara
- Department of Dermatology; Nagasaki University Graduate School of Biomedical Sciences; Nagasaki Japan
| | - R. Fukuchi
- Department of Dermatology; Nagasaki University Graduate School of Biomedical Sciences; Nagasaki Japan
| | - Y. Sato
- Department of Dermatology; Nagasaki University Graduate School of Biomedical Sciences; Nagasaki Japan
| | - S. Kuwatsuka
- Department of Dermatology; Nagasaki University Graduate School of Biomedical Sciences; Nagasaki Japan
| | - T. Takeichi
- Department of Dermatology; Nagoya University Graduate School of Medicine; Nagoya Japan
| | - M. Akiyama
- Department of Dermatology; Nagoya University Graduate School of Medicine; Nagoya Japan
| | - K. Sugiura
- Department of Dermatology; Fujita Health University School of Medicine; Toyoake Japan
| | - A. Utani
- Department of Dermatology; Nagasaki University Graduate School of Biomedical Sciences; Nagasaki Japan
| |
Collapse
|
40
|
Okubo M, Noguchi S, Kimura E, Mitsuhashi S, Nishino I. Comprehensive analysis: Nonsense mutation induced exon skipping in Becker muscular dystrophy. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.050] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
41
|
Kawase Y, Kawasaki M, Omori H, Tanigaki T, Okamoto S, Ota H, Kikuchi J, Okubo M, Kamiya H, Hirakawa A, Suzuki T, Matsuo H. P1745An old but new method for induction of hyperaemia: A validation study. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p1745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
42
|
Flambard A, Sugahara A, De S, Okubo M, Yamada A, Lescouëzec R. Probing the local structure of Prussian blue electrodes by 113Cd NMR spectroscopy. Dalton Trans 2017; 46:6159-6162. [PMID: 28426074 DOI: 10.1039/c7dt00728k] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
We demonstrate that 113Cd NMR is a potent technique to monitor the local electronic and structural states of the Prussian blue electrode during Li+ intercalation, providing an atomic-scale insight into the reaction mechanism.
Collapse
Affiliation(s)
- A Flambard
- Sorbonne Universités, UPMC Paris 6, Institut Parisien de Chimie Moléculaire, CNRS UMR 8232, 4 place Jussieu, Paris 75252, France.
| | | | | | | | | | | |
Collapse
|
43
|
Sue-eng S, Boonchuwong T, Chaiyasat P, Okubo M, Chaiyasat A. Preparation of stable poly(methacrylic acid)-b-polystyrene emulsion by emulsifier-free emulsion iodine transfer polymerization (emulsion ITP) with self-assembly nucleation. POLYMER 2017. [DOI: 10.1016/j.polymer.2016.12.067] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
44
|
Ogane M, Okubo M, Yoshikawa M, Shinomiya T, Tsukagoshi E, Kawaguchi M. Rebamipide, an anti-ulcerative drug, inhibits induction of salivary dysfunction by benzodiazepines. Oral Dis 2017; 23:511-517. [PMID: 28117549 DOI: 10.1111/odi.12642] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2015] [Revised: 01/11/2017] [Accepted: 01/17/2017] [Indexed: 11/28/2022]
Abstract
OBJECTIVES The purpose of this study was to determine whether rebamipide, an antistomach ulcer agent, ameliorated benzodiazepine-induced hyposalivation in rat parotid gland (PG) and submandibular gland (SMG). METHODS Saliva was collected from PG and SMG through a capillary cannula inserted into the parotid duct and sublingual papillae, respectively, every 15 min for 1 h after stimulation with pilocarpine dissolved in physiological saline and intraperitoneally administered at 1 mg kg-1 . Diazepam (DZP) was administered intraperitoneally at a dose of 0.2 mg kg-1 twice daily for 7 days. Rebamipide was administered at 10, 20, 30, or 100 mg kg-1 concomitantly with DZP to determine its effect on hyposalivation. The effect of rebamipide on movement of intracellular calcium ([Ca2+ ]i) in isolated parotid acinar cells was analyzed using Fluo4, a fluorescent dye used to detect Ca2+ . RESULTS Repetitive administration of DZP decreased salivary secretion in PG and SMG. This inhibitory effect was weakened by administration of rebamipide. Prior administration of DZP (10-6 M) significantly suppressed carbachol (10-7 M)-induced increase in [Ca2+ ]i. This inhibitory effect was ameliorated by combined use with rebamipide (5 × 10-4 M). CONCLUSION This findings suggest that rebamipide weakens the downregulatory effect of DZP on salivary secretion by preventing DZP-induced suppression of increase in [Ca2+ ]i.
Collapse
Affiliation(s)
- M Ogane
- Department of Pharmacology, Tokyo Dental College, Chiyoda-ku, Japan
| | - M Okubo
- Department of Pharmacology, Tokyo Dental College, Chiyoda-ku, Japan
| | - M Yoshikawa
- Department of Clinical Pharmacology, Tokai University School of Medicine, Isehara, Japan
| | - T Shinomiya
- Department of Pharmacology, Tokyo Dental College, Chiyoda-ku, Japan
| | - E Tsukagoshi
- Department of Pharmacology, Tokyo Dental College, Chiyoda-ku, Japan
| | - M Kawaguchi
- Department of Pharmacology, Tokyo Dental College, Chiyoda-ku, Japan
| |
Collapse
|
45
|
Okubo M, Minami N, Goto K, Noguchi S, Mitsuhashi S, Nishino I. Genetic diagnosis of Duchenne/Becker muscular dystrophy using next-generation sequencing: Validation analysis of DMD mutations. Neuromuscul Disord 2016. [DOI: 10.1016/j.nmd.2016.06.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
46
|
Okubo M, Shoda H, Bannai E, Kubo K, Kanda H, Fujio K, Yamamoto K. Systemic lupus erythematosus with ADAMTS13 inhibitor-negative thrombotic microangiopathy treated with combination of mycophenolate mofetil, plasma exchange and steroid. Lupus 2016; 26:334-336. [PMID: 27416846 DOI: 10.1177/0961203316659547] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- M Okubo
- Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
| | - H Shoda
- Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
| | - E Bannai
- Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
| | - K Kubo
- Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
| | - H Kanda
- Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
| | - K Fujio
- Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
| | - K Yamamoto
- Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
| |
Collapse
|
47
|
Okubo M, Xu DH, Kanaida K, Matsumoto T. Localization of carboxyl groups at surface layer of carboxylated polymer emulsion particles by alkali treatment. Colloid Polym Sci 2016. [DOI: 10.1007/bf01412714] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
48
|
Yamanaka H, Kobayashi K, Okubo M, Noguchi K. Annexin A2 in primary afferents contributes to neuropathic pain associated with tissue type plasminogen activator. Neuroscience 2016; 314:189-99. [DOI: 10.1016/j.neuroscience.2015.11.058] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2015] [Revised: 11/21/2015] [Accepted: 11/25/2015] [Indexed: 02/07/2023]
|
49
|
Nagaoka S, Shinbara H, Okubo M, Kawakita T, Hino K, Sumiya E. Contributions of ADP and ATP to the increase in skeletal muscle blood flow after manual acupuncture stimulation in rats. Acupunct Med 2016; 34:229-34. [PMID: 26746172 DOI: 10.1136/acupmed-2015-010959] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2015] [Accepted: 12/13/2015] [Indexed: 11/03/2022]
Abstract
OBJECTIVE To investigate the contributions of adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to the increase in skeletal muscle blood flow (MBF) observed following manual acupuncture (MA) stimulation in rats. METHODS Male Sprague-Dawley rats were used as experimental animals (300-370 g, n=40). MA was applied to the right tibialis anterior muscle (TA) for 1 min using a stainless steel acupuncture needle. In eight rats, high-performance liquid chromatography with the microdialysis technique was used to measure local extracellular concentrations of ATP, ADP, adenosine monophosphate (AMP), and adenosine in the TA. In the remaining 32 rats, fluorescent microspheres (15 µm in diameter) were used to measure MBF in the TA following pre-treatment with either the P2 receptor antagonist suramin (100 mg/kg intra-arterially) or saline (control) (n=16 each). Rats receiving MA (Suramin+MA and Saline+MA groups, n=8 each) were compared with untreated rats (Suramin and Saline groups, n=8). RESULTS MA significantly increased the local extracellular concentration of ATP, ADP, and adenosine (p<0.05, before MA vs 30 min after MA). In addition, MA significantly increased MBF in rats pre-treated with saline or suramin (p<0.01, Saline vs Saline+MA; p<0.05, Suramin vs Suramin+MA, respectively). However, suramin significantly suppressed this MA-induced increase in MBF (p<0.05, Saline+MA vs Suramin+MA). CONCLUSIONS These results suggest that both ATP and ADP partially contribute to the MA-induced increase in MBF via P2 receptors. However, further studies are needed to clarify the contributions of other vasodilators.
Collapse
Affiliation(s)
- S Nagaoka
- Department of Basic Acupuncture and Moxibustion, Meiji University of Integrative Medicine, Nantan-shi, Kyoto, Japan
| | - H Shinbara
- Department of Basic Acupuncture and Moxibustion, Meiji University of Integrative Medicine, Nantan-shi, Kyoto, Japan
| | - M Okubo
- Department of Anatomy and Neuroscience, Hyogo College of Medicine, Nishinomiya-shi, Hyogo, Japan
| | - T Kawakita
- Department of Basic Acupuncture and Moxibustion, Meiji University of Integrative Medicine, Nantan-shi, Kyoto, Japan
| | - K Hino
- Department of Basic Acupuncture and Moxibustion, Meiji University of Integrative Medicine, Nantan-shi, Kyoto, Japan
| | - E Sumiya
- Department of Basic Acupuncture and Moxibustion, Meiji University of Integrative Medicine, Nantan-shi, Kyoto, Japan
| |
Collapse
|
50
|
Chaiyasat P, Namwong S, Okubo M, Chaiyasat A. Synthesis of micrometer-sized poly(methyl methacrylate) particles by microsuspension iodine transfer polymerization (ms ITP). RSC Adv 2016. [DOI: 10.1039/c6ra19288b] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Micrometer-sized poly(methyl methacrylate) (PMMA) particles were successfully prepared without submicrometer-sized by-products for the first time by applying microsuspension iodine transfer polymerization with iodoform as a chain transfer agent.
Collapse
Affiliation(s)
- P. Chaiyasat
- Department of Chemistry
- Faculty of Science and Technology
- Rajamangala University of Technology Thanyaburi
- Pathumthani 12110
- Thailand
| | - S. Namwong
- Department of Chemistry
- Faculty of Science and Technology
- Rajamangala University of Technology Thanyaburi
- Pathumthani 12110
- Thailand
| | - M. Okubo
- Department of Chemistry
- Faculty of Science and Technology
- Rajamangala University of Technology Thanyaburi
- Pathumthani 12110
- Thailand
| | - A. Chaiyasat
- Department of Chemistry
- Faculty of Science and Technology
- Rajamangala University of Technology Thanyaburi
- Pathumthani 12110
- Thailand
| |
Collapse
|